Abstract
The use of antipsychotic medications presents a trade-off for the treating physician. On the one hand, there is enough literature regarding the efficacy of these medications to support their judicial use, while on the other, chronic and at time impairing side effects are troubling to both physicians and the patients. Extrapyramidal side effects are the hallmark of first-generation antipsychotics, while metabolic side effects including weight gain, diabetes mellitus, and lipid abnormalities are more common with second-generation antipsychotics. This article presents a concise overview of the current literature on antipsychotic-related side effects and treatment options.
Keywords: Mental health, children, and adolescents, psychopharmacology, antipsychotics, side effects, psychotropics.
Current Psychopharmacology
Title:Management of Adverse Effects from Atypical Antipsychotics
Volume: 7
Author(s): Ahsan Nazeer*Joseph L. Calles
Affiliation:
- Department of Psychiatry, Sidra Medical and Research Center. C2M 224, 2nd Mezzanine, OPC, PO Box 26999, Al Luqta Street, Education City North Campus, Qatar Foundation, Doha,Qatar
Keywords: Mental health, children, and adolescents, psychopharmacology, antipsychotics, side effects, psychotropics.
Abstract: The use of antipsychotic medications presents a trade-off for the treating physician. On the one hand, there is enough literature regarding the efficacy of these medications to support their judicial use, while on the other, chronic and at time impairing side effects are troubling to both physicians and the patients. Extrapyramidal side effects are the hallmark of first-generation antipsychotics, while metabolic side effects including weight gain, diabetes mellitus, and lipid abnormalities are more common with second-generation antipsychotics. This article presents a concise overview of the current literature on antipsychotic-related side effects and treatment options.
Export Options
About this article
Cite this article as:
Nazeer Ahsan *, Calles L. Joseph , Management of Adverse Effects from Atypical Antipsychotics, Current Psychopharmacology 2018; 7 (1) . https://dx.doi.org/10.2174/2211556007666180220162945
DOI https://dx.doi.org/10.2174/2211556007666180220162945 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PDE-5 Inhibitors: Clinical Points
Current Drug Targets Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology The Metformin Paradox
Current Diabetes Reviews Pharmacological Properties of Thalidomide and its Analogues
Recent Patents on Inflammation & Allergy Drug Discovery Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Cardiovascular Risk Factors: Does Sex Matter?
Current Vascular Pharmacology Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target
Current Pharmaceutical Design Three-Dimensional Ultrasound in Fetal Size and Growth Assessment
Current Medical Imaging New Treatments for COPD in the Elderly
Current Pharmaceutical Design Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Schiff Bases of Istain: Antiglycation Activity
Letters in Drug Design & Discovery Mitochondrial Dysfunction, Oxidative Stress and Diabetic Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Contribution of Large Animals to Translational Research on Prenatal Programming of Obesity and Associated Diseases
Current Pharmaceutical Biotechnology The NPC1L1 Inhibitor Ezetimibe in the Treatment of the Dyslipidemia in Patients Affected by the Metabolic Syndrome: Evidences and Perspectives
Current Enzyme Inhibition Pharmacogenomics in Psychiatry: Implications for Practice
Recent Patents on Biotechnology Diabetic CVD – Soluble Epoxide Hydrolase as A Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research